We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Living Cell Technologies’ Accepts Proposed Revised Conditions for Diabetes Clinical Trial in New Zealand
News

Living Cell Technologies’ Accepts Proposed Revised Conditions for Diabetes Clinical Trial in New Zealand

Living Cell Technologies’ Accepts Proposed Revised Conditions for Diabetes Clinical Trial in New Zealand
News

Living Cell Technologies’ Accepts Proposed Revised Conditions for Diabetes Clinical Trial in New Zealand

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Living Cell Technologies’ Accepts Proposed Revised Conditions for Diabetes Clinical Trial in New Zealand"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Living Cell Technologies Limited has announced the Company has accepted a preliminary decision from the New Zealand Minister of Health, the Honorable Tony Ryall, to issue a new conditional authorization for its New Zealand Phase I/IIa clinical trial of DIABECELL® for insulin dependent diabetes.

The Minister’s letter states that “the proposed condition that would require (LCT) to amend the inclusion criteria of (LCT’s) study to limit participation in the study to patients with brittle diabetes who suffer from significant metabolic instability is essential to ensure that the study complies with international guidelines, which require that participants obtain maximum benefit possible from their participation in the study”.

“The other proposed changes to the existing conditions are matters that LCT has agreed are appropriate during the peer review process, or are changes of a procedural, rather than a substantive nature ….”

The Company said that the clinical protocol for the New Zealand diabetes trial has already been amended according to the proposed new conditions from the Minister. LCT is pleased to have worked with the Ministry of Health to finalize the protocols for the clinical trial of DIABECELL®.
Advertisement